Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.



George Tofaris graduated from the combined MB/PhD programme of Cambridge University in 2003. He completed his general medical training at the National Hospital for Neurology, Hammersmith, Royal Brompton and Royal Free hospitals in London in 2006. He worked for a year at the Neurology Department of the Austin hospital, an affiliate of Melbourne University and was appointed Clinical Lecturer at Oxford in 2007. He was awarded a Lefler fellowship from Harvard Medical School in 2008-09 for advanced studies in neurodegenerative diseases. In 2011, he completed his training in Clinical Neurology at Oxford and was awarded a Wellcome Trust Intermediate Clinical Fellowship and the Wellcome-Beit Prize. He heads the EU IMI Consortium IMPRiND which aims to delineate new mechanisms that are relevant to the progression of pathology in Parkinson's and Alzheimer's disease. He held a Todd-Bird Junior Research Fellowship in Medicine at New College and was the recipient of the biennial Cornelli Prize for research in Parkinson's disease and the Junior Investigator Award from the International Movement Disorder Society.  As a clinically active Consultant Neurologist at the John Radcliffe hospital, he covers acute as well as general outpatient neurology and leads regional specialist clinics in Movement and Neurogenetic Disorders.

George Tofaris


Wellcome Trust Clinician Scientist Associate Professor

  • Honorary Consultant Neurologist

Research Summary

We are studying basic cellular pathways that could inform the development of targeted biological therapies in neurodegenerative and neurogenetic disorders. To this end, we use Drosophila models and iPSc-derived neurons to identify cellular perturbations in response to expression of toxic proteins implicated in neurodegeneration and a range of biochemical assays to understand underlying mechanisms.

Of particular interest to our group is the study of ubiquitin-dependent lysosomal degradation pathways. It is now well established that transport of proteins or organelles to lysosomes and their subsequent degradation is especially relevant to Parkinson’s disease. An important signalling cascade in this pathway is the conjugation of a ubiquitin chain to protein-substrates or organelles such as mitochondria.  This is a three-step catalytic process, involving a ubiquitin activating enzyme E1, a ubiquitin conjugating enzyme E2 and a ubiquitin ligase E3. There are more than 650 E3s, which regulate substrate specificity and different types of ubiquitin chains, which determine the cellular fate of the ubiquitinated substrates.

We first demonstrated that α-synuclein is ubiquitinated in Lewy bodies and subsequently identified Nedd4 as a critical E3 in α-synuclein trafficking and toxicity. More recently we showed that in human brain, the expression of the deubiquitinase Usp8 is increased in dopaminergic neurons with Lewy bodies, opposing α-synuclein clearance and increasing its toxicity in the Drosophila model.  Because the cellular accumulation of α-synuclein is causatively linked to neurodegeneration, our findings suggest novel mechanistic insights into the pathogenesis of Parkinson's and related diseases, which are the focus of current studies.

We are also interested in the role of mitochondrial dysfunction in  hereditary forms of neurodegeneration and the study of circulating exosomes as potential markers for Parkinson's disease stratification.  

Sources of Funding

  • Wellcome Trust 
  • EPSRC 
  • British Medical Association
  • Alzheimer's Research UK 
  • NIHR Oxford BRC
  • EU Innovative Medicines Initiative

Key publications

Recent publications

More publications